Becton Dickinson Pre-Tax Profit Margin 2010-2023 | BDX
Current and historical pre-tax profit margin for Becton Dickinson (BDX) from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Becton Dickinson pre-tax profit margin for the three months ending December 31, 2023 was .
| Becton Dickinson Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2023-12-31 |
$19.49B |
$1.54B |
7.90% |
| 2023-09-30 |
$19.37B |
$1.66B |
8.58% |
| 2023-06-30 |
$19.05B |
$1.80B |
9.46% |
| 2023-03-31 |
$18.81B |
$1.75B |
9.31% |
| 2022-12-31 |
$18.74B |
$1.66B |
8.88% |
| 2022-09-30 |
$18.87B |
$1.78B |
9.45% |
| 2022-06-30 |
$18.41B |
$1.32B |
7.14% |
| 2022-03-31 |
$18.38B |
$1.27B |
6.92% |
| 2021-12-31 |
$18.53B |
$1.14B |
6.12% |
| 2021-09-30 |
$19.13B |
$1.69B |
8.84% |
| 2021-06-30 |
$18.57B |
$1.41B |
7.60% |
| 2021-03-31 |
$17.82B |
$1.28B |
7.19% |
| 2020-12-31 |
$17.16B |
$1.18B |
6.86% |
| 2020-09-30 |
$16.07B |
$0.41B |
2.58% |
| 2020-06-30 |
$16.92B |
$0.84B |
4.97% |
| 2020-03-31 |
$17.41B |
$1.05B |
6.05% |
| 2019-12-31 |
$17.36B |
$0.86B |
4.93% |
| 2019-09-30 |
$17.29B |
$1.18B |
6.80% |
| 2019-06-30 |
$17.11B |
$1.59B |
9.31% |
| 2019-03-31 |
$17.04B |
$1.78B |
10.44% |
| 2018-12-31 |
$17.06B |
$1.78B |
10.44% |
| 2018-09-30 |
$15.98B |
$1.17B |
7.34% |
| 2018-06-30 |
$14.75B |
$1.08B |
7.35% |
| 2018-03-31 |
$13.50B |
$0.03B |
0.24% |
| 2017-12-31 |
$12.25B |
$0.39B |
3.18% |
| 2017-09-30 |
$12.09B |
$0.98B |
8.07% |
| 2017-06-30 |
$12.16B |
$0.66B |
5.43% |
| 2017-03-31 |
$12.32B |
$1.49B |
12.06% |
| 2016-12-31 |
$12.42B |
$1.50B |
12.08% |
| 2016-09-30 |
$12.48B |
$1.07B |
8.60% |
| 2016-06-30 |
$12.31B |
$1.25B |
10.19% |
| 2016-03-31 |
$12.23B |
$0.87B |
7.12% |
| 2015-12-31 |
$11.22B |
$0.72B |
6.42% |
| 2015-09-30 |
$10.28B |
$0.74B |
7.19% |
| 2015-06-30 |
$9.42B |
$0.93B |
9.83% |
| 2015-03-31 |
$8.46B |
$1.31B |
15.48% |
| 2014-12-31 |
$8.48B |
$1.45B |
17.07% |
| 2014-09-30 |
$8.45B |
$1.52B |
18.02% |
| 2014-06-30 |
$8.35B |
$1.21B |
14.44% |
| 2014-03-31 |
$8.24B |
$1.16B |
14.09% |
| 2013-12-31 |
$8.17B |
$1.16B |
14.18% |
| 2013-09-30 |
$8.05B |
$1.17B |
14.46% |
| 2013-06-30 |
$7.92B |
$1.47B |
18.51% |
| 2013-03-31 |
$7.85B |
$1.51B |
19.19% |
| 2012-12-31 |
$7.78B |
$1.52B |
19.49% |
| 2012-09-30 |
$7.71B |
$1.47B |
19.09% |
| 2012-06-30 |
$7.61B |
$1.46B |
19.15% |
| 2012-03-31 |
$7.58B |
$1.47B |
19.43% |
| 2011-12-31 |
$7.57B |
$1.53B |
20.21% |
| 2011-09-30 |
$7.58B |
$1.62B |
21.32% |
| 2011-06-30 |
$7.34B |
$1.59B |
21.67% |
| 2011-03-31 |
$7.22B |
$1.57B |
21.73% |
| 2010-12-31 |
$7.10B |
$1.55B |
21.87% |
| 2010-09-30 |
$7.12B |
$1.57B |
22.00% |
| 2010-06-30 |
$7.22B |
$1.62B |
22.47% |
| 2010-03-31 |
$7.21B |
$1.64B |
22.73% |
| 2009-12-31 |
$7.14B |
$1.58B |
22.14% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$67.554B |
$19.372B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
